BRPI0516735A - esquema de sìntese melhorada para lacosamida - Google Patents

esquema de sìntese melhorada para lacosamida

Info

Publication number
BRPI0516735A
BRPI0516735A BRPI0516735-3A BRPI0516735A BRPI0516735A BR PI0516735 A BRPI0516735 A BR PI0516735A BR PI0516735 A BRPI0516735 A BR PI0516735A BR PI0516735 A BRPI0516735 A BR PI0516735A
Authority
BR
Brazil
Prior art keywords
lacosamide
synthesis scheme
improved synthesis
compound
formula
Prior art date
Application number
BRPI0516735-3A
Other languages
English (en)
Inventor
Jens Riedner
Gavin Dunne
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of BRPI0516735A publication Critical patent/BRPI0516735A/pt
Publication of BRPI0516735B1 publication Critical patent/BRPI0516735B1/pt
Publication of BRPI0516735B8 publication Critical patent/BRPI0516735B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1854—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/10—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESQUEMA DE SìNTESE MELHORADA PARA LACOSAMIDA. A presente invenção refere-se a um método melhorado de produção de (R)-2-acetamido-N-benzil-3 metoxipropionamida (lacosamida) que compreende a O-metilação de um composto da fórmula I para produzir um composto da fórmula II em uma reação da etapa única.
BRPI0516735A 2004-10-02 2005-09-30 métodos para produção de (r)-2-acetamido-n-benzil-3-metoxipropionamida (lacosamida) e de uma formulação farmacêutica, e uso de (r)-n-benzil-2-nboc-amino-3-metoxipropionamida (c-937) BRPI0516735B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04023556.6 2004-10-02
EP04023556A EP1642889A1 (en) 2004-10-02 2004-10-02 Improved synthesis scheme for lacosamide
PCT/EP2005/010603 WO2006037574A1 (en) 2004-10-02 2005-09-30 Improved synthesis scheme for lacosamide

Publications (3)

Publication Number Publication Date
BRPI0516735A true BRPI0516735A (pt) 2008-09-23
BRPI0516735B1 BRPI0516735B1 (pt) 2021-01-12
BRPI0516735B8 BRPI0516735B8 (pt) 2021-05-25

Family

ID=34926827

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516735A BRPI0516735B8 (pt) 2004-10-02 2005-09-30 métodos para produção de (r)-2-acetamido-n-benzil-3-metoxipropionamida (lacosamida) e de uma formulação farmacêutica, e uso de (r)-n-benzil-2-nboc-amino-3-metoxipropionamida (c-937)

Country Status (24)

Country Link
US (2) US7884134B2 (pt)
EP (2) EP1642889A1 (pt)
JP (1) JP5128281B2 (pt)
KR (1) KR101246169B1 (pt)
CN (2) CN1989102B (pt)
AT (1) ATE457975T1 (pt)
AU (1) AU2005291456B2 (pt)
BR (1) BRPI0516735B8 (pt)
CA (1) CA2570598C (pt)
CY (1) CY1109994T1 (pt)
DE (1) DE602005019437D1 (pt)
DK (1) DK1799635T3 (pt)
EA (1) EA012588B1 (pt)
ES (1) ES2341470T3 (pt)
HR (1) HRP20100239T1 (pt)
IL (1) IL180479A (pt)
MX (1) MX2007001253A (pt)
NO (1) NO336765B1 (pt)
NZ (1) NZ552076A (pt)
PL (1) PL1799635T3 (pt)
SI (1) SI1799635T1 (pt)
UA (1) UA95600C2 (pt)
WO (1) WO2006037574A1 (pt)
ZA (1) ZA200610000B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2262567T3 (es) 2001-03-20 2006-12-01 Schwarz Pharma Ag Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico.
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US8008351B2 (en) * 2004-04-16 2011-08-30 Ucb Pharma Gmbh Methods for prophylaxis or treatment of conditions associated with cortical spreading depression
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
NZ552651A (en) * 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
WO2007059805A1 (de) 2005-11-24 2007-05-31 Kronospan Technical Company Ltd. BESCHICHTUNGSANLAGE MIT FLIEßFÄHIGEM BESCHICHTUNGSMATERIAL FÜR GLATTE ODER STRUKTURIERTE OBERFLÄCHEN
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP2037965B1 (en) 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2009053070A1 (en) * 2007-10-23 2009-04-30 Schwarz Pharma Ag Compounds for treating demyelination conditions
US8093426B2 (en) 2007-12-04 2012-01-10 Ranbaxy Laboratories Limited Intermediate compounds and their use in preparation of lacosamide
WO2009146325A1 (en) 2008-05-28 2009-12-03 Pliva Hrvatska D.O.O. Polymorphic and amorphous forms of lacosamide and amorphous compositions
ES2408208T3 (es) * 2008-11-07 2013-06-19 Ucb Pharma Gmbh Nuevo procedimiento para preparar derivados de aminoácidos.
DE102008059155A1 (de) 2008-11-27 2010-06-02 Ratiopharm Gmbh Trockenverarbeitung und neue Formen von Lacosamid
CN101591300B (zh) * 2009-02-19 2011-05-04 成都伊诺达博医药科技有限公司 合成拉考沙胺的新方法
WO2010107993A2 (en) 2009-03-18 2010-09-23 Pliva Hrvatska D.O.O. Process for preparing (r)-7v-benzyl-2- (benyloxycarbonylamino)-s-methoxypropionamide
US8440861B2 (en) 2009-08-06 2013-05-14 Medichem, S.A. Solid forms of an N-(phenylmethyl)propanamide derivative and processes of preparation
CN102020589B (zh) * 2009-09-19 2013-11-06 浙江九洲药业股份有限公司 一种氨基甲酸叔丁酯衍生物及其制备方法和应用
WO2011039781A1 (en) * 2009-09-25 2011-04-07 Cadila Healthcare Limited Processes for the preparation of lacosamide and intermediates thereof
WO2011061610A2 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Processes for preparation of polymorphic forms of lacosamide
US8853453B2 (en) 2010-01-29 2014-10-07 Ranbaxy Laboratories Limited Processes for reducing impurities in lacosamide
IT1398044B1 (it) 2010-01-29 2013-02-07 Archimica Srl Processo per la preparazione della lacosamide
CN102146048B (zh) * 2010-02-06 2013-11-13 浙江九洲药业股份有限公司 拉科酰胺中间体化合物及其制备方法和应用
US8829226B2 (en) * 2010-02-06 2014-09-09 Zhejiang Jiuzhou Pharmaceutical Co., Ltd Lacosamide intermediate compound, preparation method thereof and use thereof
US8759582B2 (en) 2010-02-08 2014-06-24 Natco Pharma Limited Process for the preparation of lacosamide
WO2011099033A1 (en) * 2010-02-09 2011-08-18 Msn Laboratories Limited Process for preparing (r)-2-acetamido-n-benzyl-3-methoxy-propionamide
WO2011130615A2 (en) * 2010-04-15 2011-10-20 Dr. Reddy's Laboratories Ltd. Preparation of lacosamide
US20130123537A1 (en) * 2010-05-17 2013-05-16 K a s s Narayan Garimella Process for the preparation of lacosamide
WO2011158194A1 (en) 2010-06-15 2011-12-22 Medichem, S.A. Enzymatic resolution of racemic (2r,s)-2-(acetylamino)-3-methoxy-n-(phenylmethyl)propanamide
EP2399901A1 (en) 2010-06-23 2011-12-28 Archimica GmbH Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide
US20130102811A1 (en) * 2010-07-02 2013-04-25 Sun Pharmaceutical Industries Ltd Process for the preparation of lacosamide
US8957252B2 (en) 2010-07-27 2015-02-17 Indoco Remedies Limited Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives
EP2621893A1 (en) 2010-10-01 2013-08-07 UCB Pharma GmbH Process for the preparation of amino acid derivatives
EP2444390B1 (en) 2010-10-19 2017-02-01 Euticals GmbH Process for producing Lacosamide
EP2487152A1 (en) 2010-11-17 2012-08-15 UCB Pharma GmbH Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine
GB201020026D0 (en) 2010-11-25 2011-01-12 Cambrex Karlskoga Ab New process
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
CN102320993B (zh) * 2011-07-13 2013-11-27 石家庄四药有限公司 一种制备(r)-2-叔丁氧羰基氨基-3-甲氧基丙酸的方法
WO2013024383A1 (en) * 2011-08-12 2013-02-21 Alembic Pharmaceuticals Limited An improved process for the preparation of lacosamide
MX337610B (es) 2011-08-29 2016-03-10 Signa S A De C V Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
WO2013072933A2 (en) * 2011-10-03 2013-05-23 Glenmark Generics Limited Process for preparation of 2-acetamido-n-benzyl-3-methoxypropionamide
EP2776388A4 (en) 2011-11-10 2015-07-08 Davuluri Ramamohan Rao AN INEDIC PROCESS FOR THE PREPARATION OF (R) -N-BENZYL-2-ACETAMIDO-3-METHOXYPROPIONAMIDE
JP2014533292A (ja) 2011-11-15 2014-12-11 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｎ−置換された２−（アセチルアミノ）−ｎ’−ベンジル−３−メトキシプロパンアミドの製造方法
US8748660B2 (en) 2012-07-09 2014-06-10 Council Of Scientific & Industrial Research Process for the synthesis of antiepileptic drug lacosamide
CN102816083B (zh) * 2012-07-30 2015-09-23 永光制药有限公司 拉科酰胺的制备方法
GB201219627D0 (en) 2012-11-01 2012-12-12 Cambrex Karlskoga Ab New process
WO2014155264A1 (en) 2013-03-25 2014-10-02 Jubilant Life Sciences Limited Process for the preparation of lacosamide using novel intermediates
CN103342655A (zh) * 2013-07-02 2013-10-09 扬州大学 取代乙二酮双苯胺希夫碱合成取代酰胺的新方法
KR101578979B1 (ko) * 2013-11-08 2015-12-18 에스티팜 주식회사 라코사마이드의 제조방법
MX2017002609A (es) 2014-08-28 2017-05-30 Davuluri Ramamohan Rao Procedimiento mejorado para la preparacion de lacosamida y su intermediario novedoso.
JPWO2016039393A1 (ja) * 2014-09-10 2017-06-22 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
CN104761465B (zh) * 2015-03-18 2017-05-31 四川同晟生物医药有限公司 一种拉科酰胺的制备方法
CN106699605B (zh) * 2015-07-21 2019-08-20 上海医药集团股份有限公司 一种拉科酰胺中间体的甲基化方法
CN106699595B (zh) * 2015-07-21 2019-04-12 上海医药集团股份有限公司 一种拉科酰胺制备方法
IN2015CH05001A (pt) 2015-09-18 2015-10-16 Divis Lab Ltd
US10975117B2 (en) 2015-11-13 2021-04-13 Api Corporation Method for producing lacosamide and intermediate thereof
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
US9718765B1 (en) 2016-06-21 2017-08-01 Sci Pharmtech, Inc. Process for preparation of optically pure N-substituted-3-methoxypropionic acid derivatives
US10414720B2 (en) * 2016-09-28 2019-09-17 Unichem Laboratories Ltd. Process for the preparation of lacosamide
CN106811492B (zh) * 2017-01-18 2019-11-01 长兴制药股份有限公司 一种拉科酰胺的制备方法
KR20190081386A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 루핀아마이드를 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CN110320291A (zh) * 2019-06-21 2019-10-11 山东省药学科学院 一种hplc法定量检测拉考沙胺注射液含量的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5129456A (en) * 1974-08-30 1976-03-12 Tanabe Seiyaku Co Kogakukatsusei oo benjiruserinjudotai no seiho
JPS62132849A (ja) * 1985-12-04 1987-06-16 Toray Ind Inc Ｄ−またはＬ−Ｎ−ｔ−ブトキシカルボニル−Ｏ−ベンジルセリンの製造方法
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
DE69729392T2 (de) * 1996-03-15 2005-06-02 Research Corp. Technologies, Inc., Tucson Krampfhemmende enantiomere Aminosäurederivate
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
JP3996671B2 (ja) * 1997-07-09 2007-10-24 タマ化学工業株式会社 Ｎ−アルコキシカルボニル化、ｎ−アルケニルオキシカルボニル化またはｎ−アリールアルコキシカルボニル化されたアミノ酸類の製造方法
MXPA03001458A (es) * 2000-08-17 2004-05-04 Teva Pharma Derivados de acido valproico para el tratamiento del dolor.
ES2262567T3 (es) * 2001-03-20 2006-12-01 Schwarz Pharma Ag Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico.
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
WO2004014895A1 (en) * 2002-08-05 2004-02-19 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US8008351B2 (en) * 2004-04-16 2011-08-30 Ucb Pharma Gmbh Methods for prophylaxis or treatment of conditions associated with cortical spreading depression
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
NZ552651A (en) * 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP2037965B1 (en) * 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
WO2009053070A1 (en) * 2007-10-23 2009-04-30 Schwarz Pharma Ag Compounds for treating demyelination conditions
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
AU2011335415B2 (en) * 2010-12-02 2016-05-19 Ucb Pharma Gmbh Once daily formulation of lacosamide

Also Published As

Publication number Publication date
AU2005291456B2 (en) 2011-02-24
ES2341470T3 (es) 2010-06-21
HRP20100239T1 (hr) 2010-06-30
IL180479A (en) 2011-09-27
EP1799635B1 (en) 2010-02-17
NO20072250L (no) 2007-04-30
BRPI0516735B1 (pt) 2021-01-12
JP2008514669A (ja) 2008-05-08
AU2005291456A1 (en) 2006-04-13
ZA200610000B (en) 2007-08-29
UA95600C2 (en) 2011-08-25
SI1799635T1 (sl) 2010-06-30
US20110130350A1 (en) 2011-06-02
CA2570598C (en) 2013-12-17
MX2007001253A (es) 2008-10-02
NO336765B1 (no) 2015-10-26
CN1989102B (zh) 2011-04-20
US8809585B2 (en) 2014-08-19
ATE457975T1 (de) 2010-03-15
DE602005019437D1 (pt) 2010-04-01
EP1642889A1 (en) 2006-04-05
WO2006037574A1 (en) 2006-04-13
NZ552076A (en) 2010-09-30
KR20070057778A (ko) 2007-06-07
IL180479A0 (en) 2007-06-03
DK1799635T3 (da) 2010-05-17
CY1109994T1 (el) 2014-09-10
PL1799635T3 (pl) 2010-10-29
JP5128281B2 (ja) 2013-01-23
EA200700746A1 (ru) 2007-08-31
US20080027137A1 (en) 2008-01-31
EP1799635A1 (en) 2007-06-27
CA2570598A1 (en) 2006-04-13
US7884134B2 (en) 2011-02-08
CN101928230A (zh) 2010-12-29
KR101246169B1 (ko) 2013-03-21
CN1989102A (zh) 2007-06-27
CN101928230B (zh) 2012-11-07
BRPI0516735B8 (pt) 2021-05-25
EA012588B1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
BRPI0516735A (pt) esquema de sìntese melhorada para lacosamida
EA200801607A1 (ru) Производные бензимидазолонкарбоновой кислоты
ATE402173T1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
DK1720823T3 (da) Ny fremgangsmåde til syntese af substituerede alpha-amino-indanderivater
EA200701738A1 (ru) Способ получения транс-1-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-3,3-диметилпиперазина
ATE449098T1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
EA200870038A1 (ru) Способ получения аминов
MX2007007446A (es) Procesos para la produccion de 4-aminoquinazolinas.
BRPI0507318A (pt) métodos para reduzir um composto, para a produção de calcipotriol ou monoidrato de calcipotriol, e de um composto, e de reação da mistura de compostos, composto, e, uso de um composto
HN2005000474A (es) Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos utiles como inhibidores de cpla2
CY1107101T1 (el) Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ
ATE529413T1 (de) Verfahren zur synthese von aryloxydiaminopyrimidinen
EA200900008A1 (ru) Новые хиральные промежуточные продукты, способ их получения и их применение в производстве толтеродина, фезотеродина или их активных метаболитов
DE602006005349D1 (de) Verfahren zur herstellung von hydrazon-derivaten
BRPI0607720A2 (pt) processo aperfeiçoado para a preparação de diidrobenzofuranos substituìdos por (propenil dissubstituìdos) fenilalquila
DE602005010369D1 (de) 2-thiaquinolizidines als Glycosidase- und Glycosyltransferase-Inhibitoren
ATE425959T1 (de) Verfahren zur herstellung von amino- oder hydroxybenzonitrilen
BR0214445A (pt) Processos para produzir compostos e composto
ATE469141T1 (de) Verfahren zur herstellung von substituierten thiophensulfonylisocyanaten
ATE423775T1 (de) Verfahren zur herstellung von lactonen
EA200600542A1 (ru) Способ для производства thip
BR0214971A (pt) Processo para a produção de um imunossupressor
BR0208628A (pt) Processo para produzir compostos de truncamida a
ATE488489T1 (de) Verfahren zur reduktiven deshalogenierung
EA200970203A1 (ru) Новый способ получения эфира 3-амино-5-фтор-4-диалкоксипентановой кислоты

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UCB PHARMA GMBH (DE)

Free format text: NOME ALTERADO DE: SCHWARZ PHARMA AG

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.